China Sky One Medical Inc acquires production rights to four drugs
Wed. December 24, 2008; Posted: 07:53 AM
Dec 24, 2008 (M2 EQUITYBITES via COMTEX) --
CSKI |
Quote |
Chart |
News |
PowerRating -- China Sky One Medical Inc (Nasdaq: CSKI), a fully integrated
pharmaceutical company producing over-the-counter drugs in China,
declared on 23 December that the company's subsidiary, Heilongjiang
Tianlong Pharmaceutical Inc, has been granted production approval from
the State Food and Drug Administration (SFDA) in China for four of its
newly developed drugs: Dithranol ointment, Antipruritic tincture,
Antiasthma cream and Levofloxacin Lactate.
The company stated that Dithranol ointment is intended to treat
different types of psoriasis, such as plaque psoriasis, guttate
psoriasis and hypertrophy psoriasis.
Antipruritic tincture is intended to soothe itchy skin and reduce
inflammation and can also be used for infection and bruises.
Antiasthma cream is intended to treat cough, asthma and chronic
bronchitis.
Levofloxacin Lactate injection is used to treat moderate to severe
respiratory system, urinary system and digestive system infections, as
well as soft skin tissue infections. It can also treat septicemia,
urethritis and cervicitis.
Comments on this story may be sent to admin@m2.com
For full details on China Sky One Medical Inc (CSKI)
click here. China Sky One Medical Inc (CSKI) has Short Term PowerRatings of 4. Details on China Sky One Medical Inc (CSKI) Short Term PowerRatings is available at
This Link.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index